Highlights

  • 4DMedical shares have surged more than 1,031% over the past year
  • SaaS deployment expanded to 477 global sites, up 32% year-over-year
  • Pro forma cash balance reached approximately AUD 282.7 million after major Capital raises

4DMedical Ltd (ASX: 4DX) has been one of the most extraordinary performers on the Australian share market over the past year, with its stock rising more than 1,031% before experiencing a sharp intraday correction of 10.6% in the latest session.

The company’s shares recently traded at AUD 3.40, reflecting heightened Volatility following a period of rapid expansion in both valuation and commercial activity.

Despite the recent pullback, the stock remains significantly higher on a 12-month basis, driven by accelerating global adoption of its respiratory imaging platform and increasing integration of its technology across major healthcare institutions and pharmaceutical companies.

The latest quarterly update highlights a company transitioning from early commercial adoption into broader institutional deployment, particularly across the United States and Europe.

With such a steep prior rally, investors are now evaluating whether 4DMedical remains a Long-term Growth opportunity, a stock to continue holding, or one where expectations may have moved ahead of fundamentals.

 

Share Performance Reflects Strong Investor Re-Rating

4DMedical’s extraordinary share price performance over the past year reflects a major re-rating of the company’s long-term commercial potential in medical imaging and artificial intelligence-driven diagnostics.

The company operates in the respiratory imaging space, using its CT-based ventilation and perfusion technology (CT:VQ™) to provide detailed lung function analysis from standard CT scans.

Investor enthusiasm has been driven largely by the company’s transition from development-stage technology to real-world clinical adoption across leading hospitals, research institutions, and pharmaceutical companies.

However, the recent 10.6% decline in a single Trading session highlights the volatility often associated with high-growth healthcare technology stocks following extended rallies.

Despite the pullback, the stock remains significantly elevated compared with levels seen a year ago, reflecting continued investor confidence in long-term adoption potential.

Major Global Healthcare Adoption Accelerates

A key driver of 4DMedical’s momentum has been expanding adoption of its CT:VQ™ platform across major healthcare institutions globally.

During the quarter, University of Chicago Medicine expanded its agreement with the company to include an initial pre-paid scan package, marking its fifth U.S. academic medical centre to commercially adopt the technology.

In another significant milestone, Mayo Clinic began deploying CT:VQ™ under an initial 90-day evaluation arrangement, providing exposure to one of the most influential healthcare institutions in the United States.

The company also signed a contract with GlaxoSmithKline (GSK), one of the world’s largest pharmaceutical companies, to support pulmonary Drug Development using its quantitative lung imaging analytics.

These partnerships represent a shift toward broader clinical and pharmaceutical use cases, expanding beyond early research applications into real-world clinical workflows and drug development programs.

For investors, such institutional adoption is often seen as an important validation of technology Utility and scalability in regulated healthcare environments.

Expansion Into Europe and Regulatory Progress

Another major development during the quarter was the receipt of CE Mark certification for CT:VQ™, enabling commercial deployment across the European Union.

This approval opens access to one of the largest respiratory imaging markets globally and significantly expands the company’s addressable market footprint.

In parallel, Coronary Artery Calcium (CAC) analysis received regulatory clearance in Canada, further broadening the company’s diagnostic offering across different healthcare systems.

The company also announced a new reimbursement pathway in the United States following the establishment of HCPCS code G0680 by the Centers for Medicare & Medicaid Services.

This development is particularly important because reimbursement pathways often play a critical role in determining the commercial scalability of medical imaging technologies within healthcare systems.

Growth in SaaS and Imaging Volumes

4DMedical continues to scale its software-as-a-service (SaaS) model across global healthcare networks.

During Q3 FY26, the company reported that its technology is now deployed across 477 sites globally, representing a 32% year-over-year increase.

Scan volumes also reached record levels, with 86,200 scans processed during the quarter, reflecting 79% annual growth.

Underlying SaaS Revenue increased 24% year-to-date compared with the prior corresponding period, while customer receipts rose 18% year-over-year in the third quarter.

This growth reflects increasing adoption of cloud-based diagnostic tools and expanding integration into clinical workflows, particularly in respiratory care and imaging analytics.

The company’s ability to scale scan volumes and expand site deployments has been a key focus for investors evaluating long-term revenue potential.

Capital Raises Strengthen Balance Sheet Position

During the quarter, 4DMedical completed two major institutional capital raises, including a $150 million Placement in January 2026 and an additional $83 million placement in March 2026.

The combined fundraising efforts were completed at progressively higher share prices and resulted in relatively limited dilution to existing shareholders.

As a result of these capital raises, the company reported a pro forma cash balance of approximately AUD 282.7 million as at 31 March 2026.

This strong cash position provides financial flexibility to support expansion into Europe, scale commercial operations, and invest in continued technology development.

For early-stage commercial healthcare companies, strong balance sheets are often critical in supporting global regulatory expansion and customer Acquisition strategies.

index Inclusion Signals Institutional Recognition

During the quarter, 4DMedical was added to the S&P/ASX 200 Index, reflecting increased institutional recognition and Market Capitalisation growth.

Index inclusion typically leads to increased passive fund exposure and broader investor visibility, which can influence trading Liquidity and long-term ownership structures.

This milestone also reflects the company’s transition from a niche technology developer to a more widely recognised listed healthcare technology platform.

Investor Focus Turns to Commercial Execution

Despite strong technological and clinical adoption progress, investor attention is increasingly focused on commercial execution, revenue scaling, and long-term profitability pathways.

Key areas of focus include the speed of adoption across newly approved markets such as Europe, expansion of reimbursement coverage in the United States, and conversion of pilot programs at major healthcare institutions into long-term contracts.

While scan volumes and site deployments are growing rapidly, the market is still assessing how quickly these metrics translate into sustainable Recurring Revenue growth.

Volatility in the share price reflects this balance between strong long-term potential and near-term uncertainty around commercial scaling.

Conclusion

4DMedical has delivered one of the most extraordinary share price performances on the ASX over the past year, driven by rapid expansion of its respiratory imaging technology across global healthcare systems and increasing engagement with leading hospitals and pharmaceutical companies.

The company’s latest quarterly update highlighted strong growth in SaaS deployment, record scan volumes, regulatory approvals in key markets, and a significantly strengthened balance sheet following major capital raises.

However, following a sharp share price rally and recent volatility, investor focus has shifted toward commercial execution, revenue conversion, and sustained adoption across newly opened markets.

As 4DMedical transitions deeper into global commercialisation, its performance will increasingly depend on scaling clinical usage into stable, recurring revenue streams across multiple healthcare jurisdictions.